- Home
- OPRX vs TLSA Comparison
OPRX vs TLSA Comparison
Compare OPRX & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPRX | TLSA |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United Kingdom |
| Employees | 129 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.4M | 155.2M |
| IPO Year | 2008 | 2017 |
Fundamental Metrics
Financial Performance| Metric | OPRX | TLSA |
|---|---|---|
| Price | $5.97 | $1.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $16.67 | N/A |
| AVG Volume (30 Days) | ★ 443.6K | 108.5K |
| Earning Date | 03-05-2026 | 05-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.55 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $109,429,000.00 | N/A |
| Revenue This Year | $12.26 | N/A |
| Revenue Next Year | $10.41 | N/A |
| P/E Ratio | $22.74 | ★ N/A |
| Revenue Growth | ★ 18.78 | N/A |
| 52 Week Low | $5.54 | $0.73 |
| 52 Week High | $22.25 | $2.60 |
Technical Indicators
Market Signals| Indicator | OPRX | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 31.38 | 38.51 |
| Support Level | $5.54 | N/A |
| Resistance Level | $14.28 | $1.56 |
| Average True Range (ATR) | 0.59 | 0.09 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 18.03 | 8.62 |
Price Performance
Historical ComparisonAbout OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.